# Investigating changes in serum metabolome and urinary endocrine disrupting chemicals in cats with hyperthyroidism

**Authors:** Ayelet Ziv-Gal, Megan Mahoney, Nicolas Lopez-Villalobos, Arnon Gal

PMC · DOI: 10.1007/s11259-026-11169-5 · 2026-03-23

## TL;DR

This study finds that hyperthyroid cats have altered metabolites and higher levels of certain chemicals in their urine compared to healthy cats.

## Contribution

The study identifies a novel metabolomic signature and links it to endocrine-disrupting chemicals in cats with hyperthyroidism.

## Key findings

- Hyperthyroid cats had higher urinary levels of phthalates and parabens compared to controls.
- Lipid metabolism pathways were enriched in hyperthyroid cats, with altered levels of specific metabolites.
- Sphingolipid bases and creatinine were highlighted as potential predictors of thyroid status.

## Abstract

Domestic cats share indoor environments with humans and are exposed to endocrine-disrupting chemicals (EDCs) from both household sources and cat-specific products capable of disrupting thyroid hormone signaling. The prevalence of feline hyperthyroidism (FHT) continues to rise, and while some EDCs have been implicated in its etiopathogenesis, the metabolic consequences of FHT are unknown. Here, we tested whether hyperthyroid cats exhibit altered systemic metabolomic signatures that are associated with phthalate and paraben urinary levels, compared with healthy controls. Thirty-five pet cats were enrolled (16 FHT, 19 controls). Serum samples were subjected to untargeted liquid chromatography mass spectrometry metabolomics and urine paraben and phthalates metabolites were quantified by liquid chromatography-tandem mass spectrometry. Forty-six serum metabolites and three urinary EDCs differed between groups (adjusted p < 0.05). Lipid metabolism pathways were enriched (16/74 significant; Fisher’s p = 0.02; False Discovery Rate-adjusted p = 0.16). Key serum differences included lower creatinine, linoleic acid, and 1-oleoyl-sn-glycerophosphoethanolamine in FHT. Urinary mono-isobutyl phthalate, ethylparaben, and propylparaben were higher in FHT (fold change 2.58, 3.30 and 2.07). Multivariable analyses separated groups; Weighted Sub-Network Analysis highlighted modules tied to tryptophan pathways, lipid homeostasis, and xenobiotic processing. Partial Least Squares captured 91% of response variance in two factors, with high-Variable Importance in Projection contributors including vitamin K1, 2-hydroxybenzothiazole, a sphingolipid long-chain base, and L-cysteine-glutathione disulfide. A Random Forest classifier achieved a 9.38% out-of-bag error and prioritized sphingoid bases and creatinine. Hyperthyroid cats had perturbed serum lipid-metabolite levels and higher urinary phthalate and paraben biomarker levels. These integrated data support an EDC-associated metabolomic signature in FHT and motivate longitudinal and mechanistic studies to clarify causality and inform prevention.

The online version contains supplementary material available at 10.1007/s11259-026-11169-5.

Hyperthyroid cats have higher urinary levels of phthalate and parabensHyperthyroid cats have pathway-specific alterations in fatty acid metabolismHyperthyroid cats have pathway-specific alterations in steroid hormones and amino acidsHyperthyroidism is linked to lipid imbalance, tryptophan and xenobiotic metabolismSphingolipid bases are suggested as potential predictors of thyroid status

Hyperthyroid cats have higher urinary levels of phthalate and parabens

Hyperthyroid cats have pathway-specific alterations in fatty acid metabolism

Hyperthyroid cats have pathway-specific alterations in steroid hormones and amino acids

Hyperthyroidism is linked to lipid imbalance, tryptophan and xenobiotic metabolism

Sphingolipid bases are suggested as potential predictors of thyroid status

The online version contains supplementary material available at 10.1007/s11259-026-11169-5.

## Linked entities

- **Chemicals:** phthalate (PubChem CID 181977), mono-isobutyl phthalate (PubChem CID 92272), ethylparaben (PubChem CID 8434), propylparaben (PubChem CID 7175), linoleic acid (PubChem CID 5280450), vitamin K1 (PubChem CID 5284607), 2-hydroxybenzothiazole (PubChem CID 13625), L-cysteine-glutathione disulfide (PubChem CID 10455148)
- **Diseases:** hyperthyroidism (MONDO:0004425)

## Full-text entities

- **Genes:** MBP [NCBI Gene 101096421], beta-glucuronidase [NCBI Gene 493879], VIP [NCBI Gene 101101640]
- **Diseases:** euthyroidism (MESH:D005067), thyroid nodules (MESH:D016606), nodular hyperplasia (MESH:D020518), MECPP (MESH:D020268), thyrotoxicosis (MESH:C566386), impaired renal function (MESH:D007674), tumorigenesis (MESH:D063646), hypothyroidism (MESH:D007037), acute illness (MESH:D000208), PCP (MESH:D011020), adenomatous change (MESH:D011125), muscle wasting (MESH:D009133), IRIS (MESH:C535535), EDCs (MESH:D004700), hyperactivity (MESH:D006948), diabetes mellitus (MESH:D003920), carnitine deficiency (MESH:C536778), nutrient deficiencies (MESH:D007153), iodine deficiency (MESH:D003409), FHT (MESH:D006980), TOM (MESH:C536030), mTIC (MESH:C535338), thyroid adenomas (MESH:D013964), CKD (MESH:D012080), endocrinopathy (MESH:C567425), thyroid disorders (MESH:D013959), weight gain (MESH:D015430), metabolic (MESH:D008659), polyphagia (MESH:D006963), weight loss (MESH:D015431), malignant thyroid carcinoma (MESH:D009369), hyperadrenocorticism (MESH:D000308), follicular hypertrophy (MESH:D006984), VTH (MESH:D003428), thyroid (MESH:D013966), MEHP (MESH:C536238), benign adenomatous hyperplasia of the thyroid (MESH:D006965), Chronic Kidney Disease (MESH:D051436), renal insufficiency (MESH:D051437)
- **Chemicals:** cortisol (MESH:D006854), MBzP (MESH:C103325), iodine (MESH:D007455), H (MESH:D006859), Di-n-Butyl Phthalate (MESH:D003993), DEP (MESH:C007268), Levothyroxine (MESH:D013974), 3-hydroxybutyric acid (MESH:D020155), psychosine (MESH:D011609), 4-Chloro-DL-phenylalanine (-), linoleic acid (MESH:D019787), Parabens (MESH:D010226), fatty acid (MESH:D005227), tricarboxylic acid (MESH:D014233), MMP (MESH:C517284), L-carnitine (MESH:D002331), oleoyl-L-carnitine (MESH:C026968), PBDEs (MESH:D055768), cortisone (MESH:D003348), omega-6 fatty acid (MESH:D043371), ethylparaben (MESH:C012313), sphingomyelin (MESH:D013109), DMP (MESH:D014494), alpha-tocopherol (MESH:D024502), ketone (MESH:D007659), hippuric acid (MESH:C030514), Butylparaben (MESH:C038091), tryptophan (MESH:D014364), Butyl Benzyl Phthalate (MESH:C027561), Lipid (MESH:D008055), glutathione disulfide (MESH:D019803), serotonin (MESH:D012701), acetonitrile (MESH:C032159), butorphanol (MESH:D002077), 5-hydroxyindoleacetate (MESH:D006897), 3-hydroxydodecanoic acid (MESH:C022145), Phthalates (MESH:C032279), Creatinine (MESH:D003404), glycosphingolipid (MESH:D006028), glutamic acid (MESH:D018698), polyvinylchloride (MESH:D011143), quinoline (MESH:C037219), 4-methylumbelliferone (MESH:D006923), M153 (MESH:C101692), Sphingolipid (MESH:D013107), propylparaben (MESH:C006068), methanol (MESH:D000432), acetyl-L-carnitine (MESH:D000108), Dimethyl Phthalate (MESH:C024629), phospholipid (MESH:D010743), L-cysteine (MESH:D003545), MEOHP (MESH:C080276), DEHP (MESH:D004051), vitamin K1 (MESH:D010837), 5-hydroxytryptophan (MESH:D006916), AA (MESH:D000596), choline chloride (MESH:D002794), 4-hydroxyquinoline (MESH:C034010), acetyl-CoA (MESH:D000105), MEHHP (MESH:C479069)
- **Species:** Felis catus (cat, species) [taxon 9685], Fusarium sp. HT (species) [taxon 912583], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13009073/full.md

---
Source: https://tomesphere.com/paper/PMC13009073